Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,092 shares of the biopharmaceutical company’s stock after acquiring an additional 2,828 shares during the period. Principal Financial Group Inc. owned 0.16% of Regeneron Pharmaceuticals worth $181,961,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. DGS Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 13.8% during the third quarter. DGS Capital Management LLC now owns 429 shares of the biopharmaceutical company’s stock worth $451,000 after purchasing an additional 52 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $1,598,000. American Trust acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $600,000. Synovus Financial Corp lifted its position in Regeneron Pharmaceuticals by 3.4% in the third quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock valued at $1,977,000 after acquiring an additional 61 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in Regeneron Pharmaceuticals by 8.7% in the third quarter. Tidal Investments LLC now owns 6,350 shares of the biopharmaceutical company’s stock valued at $6,675,000 after acquiring an additional 510 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $708.25 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $693.00 and a 52-week high of $1,211.20. The company has a 50-day simple moving average of $827.27 and a 200-day simple moving average of $996.84. The company has a market capitalization of $77.83 billion, a PE ratio of 17.53, a P/E/G ratio of 2.19 and a beta of 0.08.

Analyst Ratings Changes

A number of analysts have recently commented on REGN shares. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Royal Bank of Canada reduced their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Citigroup assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective for the company. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,052.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.